Grufity logoGrufity logo

RXRX

9.26USD+0.02(+0.22%)Market Closed

RECURSION PHARMACEUTICALS, INC.

Market Summary

USD9.26+0.02Market Closed
0.22%

RXRX Alerts

RXRX Stock Price

RSI Chart

Valuation

Market Cap

1.9B

Price/Earnings

-8.19

Price/Sales

106.04

Price/Cashflow

-24.43

Price/Sales

Profitability

Return on Equity

-53.45%

Return on Assets

-34.78%

Fundamentals

Revenue

Revenue (TTM)

28.7M

Revenue Y/Y

419.34%

Revenue Q/Q

71.49%

Earnings

Earnings (TTM)

-246.9M

Earnings Y/Y

-27.45%

Earnings Q/Q

7.8%

Price Action

52 Week Range

21.19
(Low)(High)

Last 7 days

-5.7%

Last 30 days

-15.4%

Last 90 days

-12.2%

Trailing 12 Months

-50.7%

Financial Health

Current Ratio

5.65

Debt/Equity

0

Debt/Cashflow

-108.49

Investor Care

Shares Dilution (1Y)

3.22%

Diluted EPS (TTM)

-1.45

Financials for RECURSION PHARMACEUTICALS

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue58.8%2918541051
Operating Expenses25.5%193154
  S&GA Expenses4.9%8177705846
  R&D Expenses5.0%160152144135108
Net Income-5.6%-246.92-233.90-211.74-186.48-147.31
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-9.1%612673734610659
  Current Assets-11.8%482546619535601
    Cash Equivalents0.2%455454508285395
  Net PPE5.2%8682716555
  Goodwill0%1111-
Liabilities-4.9%2232352416760
  Current Liabilities-14.1%8397864743
  Long Term Debt-2.8%11---
Shareholder's Equity-11.3%388438494543599
  Retained Earnings-11.6%-582.06-521.60-456.06-400.08-335.10
  Additional Paid-In Capital1.1%970959950943934
Shares Outstanding0.7%174173171170169
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-27.4%-99.93-78.44-50.47-158.61-88.88
  Share Based Compensation29.9%2419181511
Cashflow From Investing252.2%149-97.87-109.02-271.74-224.09
Cashflow From Financing527.4%11-2.55458459465

Risks

What is the probability of a big loss on RXRX?

95.3%


Probability that RECURSION PHARMACEUTICALS stock will be more than 20% underwater in next one year

95.3%


Probability that RECURSION PHARMACEUTICALS stock will be more than 30% underwater in next one year.

80%


Probability that RECURSION PHARMACEUTICALS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RXRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if RECURSION PHARMACEUTICALS was unfortunately bought at previous high price.

Returns

Cumulative Returns on RXRX

Which funds bought or sold RXRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,750,000
1,750,000
0.02%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
222,000
1,024,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
NEW
-
1,138,840
1,138,840
-%
2022-11-15
JANE STREET GROUP, LLC
ADDED
44.8
173,000
367,000
-%
2022-11-15
STATE STREET CORP
ADDED
114.32
31,170,000
48,473,000
-%
2022-11-15
ADVISORY RESEARCH INC
ADDED
56.63
527,000
1,030,000
0.10%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-10.1
5,133,000
34,445,000
0.02%
2022-11-14
MIC Capital Management UK LLP
UNCHANGED
-
21,129,000
89,927,000
16.21%
2022-11-14
DEUTSCHE BANK AG\
REDUCED
-9.71
95,000
618,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying RXRX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own RXRX

RECURSION PHARMACEUTICALS News

MarketBeat

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasted to Earn FY2022 Earnings of ($1.30) Per Share.6 days ago

RXRX Fair Value

Recent SEC filings of RECURSION PHARMACEUTICALS

View All Filings
Date Filed Form Type Document
Nov 18, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 08, 2022
8-K
Current Report
Nov 08, 2022
10-Q
Quarterly Report
Nov 04, 2022
4
Insider Trading
Oct 31, 2022
SC 13D/A
13D - Major Acquisition
Oct 31, 2022
4
Insider Trading

Latest Insider Trading transactions for RXRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-17
Larson Tina Marriott
ACQUIRED
16,960
1.06
16,000
President and COO
2022-11-17
Larson Tina Marriott
SOLD
-175,402
10.9626
-16,000
President and COO
2022-11-16
Borgeson Blake
SOLD
-197,610
11.1204
-17,770
-
2022-11-15
Larson Tina Marriott
SOLD FOR TAXES
-17,232.6
11.86
-1,453
President and COO
2022-11-15
Gibson Christopher
SOLD FOR TAXES
-68,206.9
11.86
-5,751
Chief Executive Officer
2022-11-15
Virani Shafique
SOLD
-123,123
12.3123
-10,000
Chief Business Officer
2022-11-15
Virani Shafique
ACQUIRED
11,100
2.22
5,000
Chief Business Officer
2022-11-15
Secora Michael
SOLD FOR TAXES
-12,630.9
11.86
-1,065
Chief Financial Officer
2022-11-15
Virani Shafique
SOLD FOR TAXES
-7,270.18
11.86
-613
Chief Business Officer
2022-11-03
Gibson Christopher
SOLD
-5,055.2
10.1104
-500
Chief Executive Officer

1–10 of 50

Chistopher C. Gibson
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

RXRX Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue    
Revenue$ 13,160$ 2,534$ 26,167$ 7,645
Operating costs and expenses    
Cost of revenue15,409037,4350
Research and development40,83633,246111,71686,979
General and administrative19,48815,69061,76138,481
Total operating costs and expenses75,73348,936210,912125,460
Loss from operations(62,573)(46,402)(184,745)(117,815)
Other income (loss), net2,128(1,026)2,761(3,731)
Net loss$ (60,445)$ (47,428)$ (181,984)$ (121,546)
Per share data    
Net loss per share of Class A and B common stock, basic (in dollars per share)$ (0.35)$ (0.28)$ (1.06)$ (1.10)
Net loss per share of Class A and B common stock, diluted (in dollars per share)$ (0.35)$ (0.28)$ (1.06)$ (1.10)
Weighted-average shares (Class A and B) outstanding, basic (in shares)173,435,970168,533,550172,122,974110,513,231
Weighted-average shares (Class A and B) outstanding, diluted (in shares)173,435,970168,533,550172,122,974110,513,231
Operating revenue    
Revenue    
Revenue$ 13,053$ 2,500$ 26,005$ 7,500
Grant revenue    
Revenue    
Revenue$ 107$ 34$ 162$ 145

RXRX Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 454,646$ 285,116
Restricted cash2,0901,552
Accounts receivable034
Other receivables11,6359,056
Investments0231,446
Other current assets13,2477,514
Total current assets481,618534,718
Restricted cash, non-current8,1548,681
Property and equipment, net85,77764,725
Operating lease right-of-use assets33,7260
Intangible assets, net1,4571,385
Goodwill801801
Other non-current assets035
Total assets611,533610,345
Current liabilities  
Accounts payable3,8902,819
Accrued expenses and other liabilities26,75732,333
Unearned revenue46,75310,000
Notes payable9590
Operating lease liabilities5,5410
Lease incentive obligation01,416
Total current liabilities83,03646,658
Deferred rent04,110
Unearned revenue, non-current93,9096,667
Notes payable, non-current561633
Operating lease liabilities, non-current45,9930
Lease incentive obligation, non-current09,339
Total liabilities223,49967,407
Commitments and contingencies (Note 7)
Stockholders’ equity  
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of September 30, 2022 and December 31, 2021; 174,072,906 shares (Class A 166,187,697 and Class B 7,885,209) and 170,272,462 shares (Class A 160,906,245 and Class B 9,366,217) issued and outstanding as of September 30, 2022 and December 31, 2021, respectively22
Additional paid-in capital970,096943,142
Accumulated deficit(582,064)(400,080)
Accumulated other comprehensive loss0(126)
Total stockholders’ equity388,034542,938
Total liabilities and stockholders’ equity$ 611,533$ 610,345